Juris Bundulis
Juris Bundulis is the Chairman of the Board of Olpha, a pharmaceutical company focused on developing and registering new generic medications. He emphasizes the importance of local pharmaceutical production in enhancing price competition and improving patient access to healthcare.
Not in the pool (under ¢1).
Recent news mentions
Juris Bundulis explains that the brand change was made to significantly expand operations in Western markets.
Olpha atjaunojusi reģistrācijas apliecības visiem saviem medikamentiem Baltijas valstīs / Diena
Latvia· 2025-09-15
Juris Bundulis is the chairman of the board of the Latvian pharmaceutical manufacturer AS 'Olpha'.
politika, resursi, pacients / DienaLatvia· 2025-09-09
Juris Bundulis expresses happiness that clean, fresh drinking water will now be available in two locations in Olaine for children and youth.
Pie divām sportošanas vietām Olainē uzstādīti Olpha dāvāti dzeramā ūdens brīvkrāni / DienaLatvia· 2025-07-28
Juris Bundulis emphasizes the importance of supporting local manufacturers to strengthen the economy and improve public welfare.
ES un Apvienotās Karalistes tirgos nonāk jauns Olpha medikaments sirds un asinsvadu slimību ārstēšanai / DienaLatvia· 2025-06-30Juris Bundulis is the chairman of the board of 'Olpha'.
Katrs otrais Latvijas iedzīvotājs mirst no sirds un asinsvadu slimībām. Sākta sociālā kampaņa Dzirdi savu sirdi! / DienaLatvia· 2025-03-17
Juris Bundulis, the chairman of the board of Olpha, indicates that each new local company's patent-free medication creates price competition and increases patient accessibility.
Olpha reģistrācijai ES valstīs iesniegusi 38 jaunas zāles / DienaLatvia· 2025-02-20
